Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 2/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23607117 | 0.85 | NPC1 (0.51) | ATRLRRK2HDAC3HDAC1HDAC2 | |
| SCHEMBL23607120 | 0.77 | TOP1 (0.61) | KDM4ETOP1 | |
| SCHEMBL21186171 | 0.76 | NPC1 (0.62) | — | |
| SCHEMBL23607128 | 0.76 | PIM1 (0.46) | PIM1HDAC3HDAC1HDAC2KDM4E | |
| SCHEMBL25131885 | 0.74 | KDM4E (0.52) | ATRPIM1PRKCIHDAC3HDAC1 | |
| SCHEMBL13328295 | 0.73 | LRRK2 (0.78) | ATRLRRK2KDM4ETOP1 | |
| SCHEMBL30961700 | 0.72 | RAB9A (0.54) | ATRLRRK2KDM4ETOP1 | |
| SCHEMBL22130324 | 0.72 | NPC1 (0.53) | KDM4E | |
| SCHEMBL31219257 | 0.72 | NPC1 (0.53) | KDM4E | |
| SCHEMBL23607123 | 0.71 | PRKCA (0.48) | PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | ATR 231/4885LRRK2 2389/4885PIM1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.